<DOC>
	<DOCNO>NCT00280930</DOCNO>
	<brief_summary>The purpose study see happen breast density healthy postmenopausal woman treatment letrozole one year , compare treatment placebo one year . Other goal study include determine connection estrogen level breast density woman study collect information quality life take part study .</brief_summary>
	<brief_title>Letrozole Postmenopausal Women Increased Risk Breast Cancer</brief_title>
	<detailed_description>- Patients randomize one two study group . Group 1 receive letrozole Group 2 receive placebo . This double-blind trial neither patient doctor know treatment group assign . - If patient Group 1 take letrozole tablet orally day food one year . Patients Group 2 take placebo tablet orally day food one year . - Patients group also give calcium tablet ( 500mg ) vitamin D tablet ( 400IU ) day one year . - After initial screen visit , patient return clinic 3 , 6 , 9 12 month ( total 6 visit first year ) . There also two follow-up visit 18 24 month . For 3 , 9 18 month visit , telephone contact instead clinic visit allow . - The following test procedure perform visit : evaluation side effect ; routine blood test ( 6 , 12 , 24 month visit ) ; urine sample ( 6 12 month visit ) ; complete physical exam include breast exam ( 12 24 month visit ) ; mammogram ( 12 24 month visit ) ; bone marrow density x-ray test ( 12 24 month visit ) ; standard x-ray low back chest ( 12 month visit ) ; questionnaire patient feeling ( 12 24 month visit ) . - The length participation study 1 year study treatment follow 1 year follow-up .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<criteria>Postmenopausal status define : woman &gt; 55 year ageno spontaneous menses least 12 month ; woman &lt; 55 yearsno spontaneous menses within past 12 month FSH level &gt; 34.4 IU/I ; bilateral oophorectomy If subject prior invasive breast cancer must surgically remove time orginal diagnosis evidence metastasis primary tumor may receptive negative , positive equivocal Baseline mammogram ( within 6 month ) indicate mammographic density occupy &gt; 25 % ( grade 4/5 , 5/6 6/6 ) breast tissue Baseline breast examination demonstrate clinical evidence breast cancer Acceptable quality DEXA L2L4 posteroanterior ( PA ) spine hup must perform 6 month randomization Subject willing able complete quality life questionnaire either English French Mammogram suspicious breast cancer ( unless subsequently rule ) Patient 's prior malignancy eligible unless metastatic disease Uncontrolled metabolic endocrine disease , cardiovascular disease malabsorption syndrome Current chemotherapy immunotherapy Hormone replacement therapy Evista ( raloxifene ) discontinue less three month baseline mammogram Tamoxifen therapy discontinue less six month prior randomization</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2007</verification_date>
	<keyword>letrozole</keyword>
	<keyword>breast cancer</keyword>
	<keyword>menopause</keyword>
</DOC>